Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Supportive Care in Cancer
Erschienen in: Supportive Care in Cancer 8/2003

01.08.2003 | Review Article

Granisetron in the control of nausea and vomiting associated with bone marrow transplantation: a review of its efficacy and tolerability

verfasst von: H. G. Prentice

Erschienen in: Supportive Care in Cancer | Ausgabe 8/2003

Einloggen, um Zugang zu erhalten

Abstract

Cancer patients undergoing bone marrow transplantation (BMT) experience severe nausea and vomiting associated with high-dose chemotherapy agents; these emetic symptoms are compounded by total body irradiation used in many conditioning regimens. This paper reviews clinical experience with the 5-HT3 receptor antagonist granisetron, both as a single agent and in combination with other anti-emetics, in patients undergoing BMT and peripheral blood stem cell transplantation (PBSCT). Clinical studies demonstrate the efficacy (47–61% with no vomiting and no worse than mild nausea) and tolerability of granisetron. Its long half-life and duration of action may be responsible for its effective 24 h control of nausea and vomiting in BMT patients.
Literatur
1.
Abang AM, Takemoto MH, Pham T, Mandanas RA, Roy V, Selby GB et al (2000) Efficacy and safety of oral granisetron versus i.v. granisetron in patients undergoing peripheral blood progenitor cell and bone marrow transplantation. Anticancer Drugs 11: 137–142CrossRefPubMed
2.
Abbott B, Ippoliti C, Bruton J, Neumann J, Whaley R, Champlin R (1999) Antiemetic efficacy of granisetron plus dexamethasone in bone marrow transplant patients receiving chemotherapy and total body irradiation. Bone Marrow Transplant 23: 265–269
3.
Abbott B, Ippoliti C, Hecth D, Bruton J, Whaley B, Champlin R (2000) Granisetron (Kytril) plus dexamethasone for antiemetic control in bone marrow transplant patients receiving highly emetogenic chemotherapy with or without total body irradiation. Bone Marrow Transplant 25: 1279–1283
4.
Applegate GL, Mittal BB, Kletzel M, Morgan E, Johnson P, Danner K et al (1998) Outpatient total body irradiation prior to bone marrow transplantation in pediatric patients: a feasibility analysis. Bone Marrow Transplant 21: 651–652
5.
Belkacémi Y, Ozsahin M, Pène F, Rio B, Sutton L, Laporte J-P et al (1996) Total body irradiation prior to bone marrow transplantation: efficacy and safety of granisetron in the prophylaxis and control of radiation-induced emesis. Int J Radiat Oncol Biol Phys 36: 77–82
6.
Bloomer JC, Baldwin SJ, Smith GJ et al (1994) Characterisation of the cytochrome P450 enzymes involved in the in vitro metabolism of granisetron. Br J Clin Pharmacol 38(6): 273–298
7.
Blower PR. Granisetron: relating pharmacology to clinical efficacy. Supp Care Cancer 2003 11: 93–100
8.
Bubalo J, Seelig F, Karbowicz S, Maziarz RT (2001) Randomized open-label trial of dolasetron for the control of nausea and vomiting associated with high-dose chemotherapy with haematopoietic stem cell transplantation. Biol Blood Marrow Transplant 7: 439–445
9.
Dey B, Sykes M, Spitzer TR (1998) Outcomes of recipients of both bone marrow and solid organ transplants. A review. Medicine 77: 355–369CrossRefPubMed
10.
Fox-Geiman M, Fisher SG, Kiley K, McLean M, Fletcher-Gonzalez D, Roczniak L et al (1999) Double-blind randomized comparison of oral granisetron and i.v. ondansetron for regimen-related nausea and vomiting (N/V) in patients undergoing stem cell transplants. Proc Am Soc Clin Oncol 18: 592a
11.
Frakes LA, Brehm TL, Kosty MP, Miller WE, McMillan RL, Mason J et al (1997) An all oral antiemetic regimen for patients undergoing high-dose chemotherapy with peripheral blood stem cell transplant. Bone Marrow Transplant 20: 473–478
12.
Gilbert CJ et al (1998) Pharmacokinetic interaction between ondansetron and cyclophosphamide during high-dose chemotherapy for breast cancer. Cancer Chemother Pharmacol 42:497–503CrossRefPubMed
13.
Hunter AE, Prentice HG, Pothecary K, Coumar A, Collis C, Upward J et al (1991) Granisetron, a selective 5-HT3 receptor antagonist, for the prevention of radiation induced emesis during total body irradiation. Bone Marrow Transplant 7: 439–441
14.
Imamura R, Voegels R, Sperandio, F, Sennes LU, Silva R, Butugan O et al (1999) Microbiology of sinusitis in patients undergoing bone marrow transplantation. Otolaryngol Head Neck Surg 120: 279–282PubMed
15.
Kaiser R, Sezer O, Papies A et al (2002) Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes. J Clin Oncol 20: 280–511
16.
Kalaycio M, Mendez Z, Pohlman B, Overmoyer B, Boparai N, Jones E et al (1998) Continuous-infusion granisetron compared to ondansetron for the prevention of nausea and vomiting after high-dose chemotherapy. J Cancer Res Clin Oncol 124: 265–269CrossRefPubMed
17.
Lacerda JF, Martins C, Carmo JA, Lourenco ME, Araujo Pereira ME, Rodrigues A et al (2000) Randomized trial of ondansetron, granisetron, and tropisetron in the prevention of acute nausea and vomiting. Transplant Proc 32: 2680–2681
18.
Lawrence CC, Gilbert CJ, Peters WP (1996) Evaluation of symptom distress in a bone marrow transplant outpatient environment. Ann Pharmacother 30: 941–945PubMed
19.
Lehoczky O (1999) About the antiemetic effectivity of granisetron in chemotherapy-induced acute emesis: a comparison of results with intravenous and oral dosing. Neoplasma 46(2): 73–79PubMed
20.
Mihelic RA, Walton SM, Hutcherson DA, Knoche AJ (2000) Evaluation of single-dose oral ondansetron vs oral granisetron for prevention of chemotherapy-induced nausea and vomiting (NV) due to high-dose chemotherapy. Proc Am Soc Clin Oncol 19: 631a
21.
Nevo S, Vogelsang GB (2001) Acute bleeding complications in patients after bone marrow transplantation. Curr Opin Hematol 8: 319–325CrossRefPubMed
22.
Okamoto S, Takahashi S, Tanosaki R, Sakamaki H, Onozawa Y, Oh H et al (1996) Granisetron in the prevention of vomiting induced by conditioning for stem cell transplantation: a prospective randomized study. Bone Marrow Transplant 17: 679–683
23.
Orchard PJ, Rogesheske J, Burns L, Rydholm N, Larson H, DeFor TE et al (1999) A prospective randomized trial of the anti-emetic efficacy of ondansetron and granisetron during bone marrow transplantation. Biol Blood Marrow Transplant 5: 386–393
24.
Perez EA, Tiemeier T, Solberg LA (1999) Antiemetic therapy for high-dose chemotherapy with transplantation: report of a retrospective analysis of a 5-HT3 regimen and literature review. Support Care Cancer 7: 413–424CrossRefPubMed
25.
Prentice HG, Cunningham S, Gandhi L, Cunningham J, Collis C, Hamon MD (1995) Granisetron in the prevention of irradiation-induced emesis. Bone Marrow Transplant 15: 445–448
26.
Prentice HG, Kibbler K, Prentice AG (2000) Towards a targeted, risk based antifungal strategy in neutropenic patients. Br J Haematol 110(2): 273–284PubMed
27.
Roy V, Ochs L, Weisdorf D (1997) Late infections following allogeneic bone marrow transplantation: suggested strategies for prophylaxis. Leuk Lymphoma 26: 115
28.
Shibuya TY, Momin F, Abella E, Jacobs JR, Karanes C, Ratanatharathorn V et al (1995) Sinus disease in the bone marrow transplant population: incidence, risk factors, and complications. Otolaryngol Head Neck Surg 113: 705–711PubMed
29.
Slaby J, Trneny M, Prochazka B, Klener P (2000) Antiemetic efficacy of three serotonin antagonists during high-dose chemotherapy and autologous stem cell transplantation in malignant lymphoma. Neoplasma 47: 319–322PubMed
30.
Spitzer TR, Friedman CJ, Bushnell W, Frankel SR, Raschko J (2000) Double-blind, randomized, parallel-group study on the efficacy and safety of oral granisetron and oral ondansetron in the prophylaxis of nausea and vomiting in patients receiving hyperfractionated total body irradiation. Bone Marrow Transplant 26: 203–210CrossRefPubMed
31.
Stewart JR, Fajardo LF, Gillette SM, Constine LS (1995) Radiation injury to the heart. Int J Radiat Oncol Biol Phys 31: 1205–1211
Metadaten
Titel
Granisetron in the control of nausea and vomiting associated with bone marrow transplantation: a review of its efficacy and tolerability
verfasst von
H. G. Prentice
Publikationsdatum
01.08.2003
Verlag
Springer-Verlag
Erschienen in
Supportive Care in Cancer / Ausgabe 8/2003
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-003-0480-6

Weitere Artikel der Ausgabe 8/2003

Supportive Care in Cancer 8/2003 Zur Ausgabe

Original Article

Factors predicting fatigue in breast cancer patients

Forthcoming Meetings

August 2003

Original Article

Randomized double-blind study of the Reliefband as an adjunct to standard antiemetics in patients receiving moderately-high to highly emetogenic chemotherapy

Short Communication

Complementary and alternative medicine (CAM) use among elderly Australian women who have cancer

Original Article

Randomized study of dexamethasone treatment for delayed emesis, anorexia and fatigue induced by irinotecan

Original Article

Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronate

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

23.04.2024 Medikamente in Schwangerschaft und Stillzeit Nachrichten

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise